Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma / Connors, Joseph M; Jurczak, Wojciech; Straus, David J; Ansell, Stephen M; Kim, Won S; Gallamini, Andrea; Younes, Anas; Alekseev, Sergey; Illés, Árpád; Picardi, Marco; Lech-Maranda, Ewa; Oki, Yasuhiro; Feldman, Tatyana; Smolewski, Piotr; Savage, Kerry J; Bartlett, Nancy L; Walewski, Jan; Chen, Robert; Ramchandren, Radhakrishnan; Zinzani, Pier L; Cunningham, David; Rosta, Andras; Josephson, Neil C; Song, Eric; Sachs, Jessica; Liu, Rachael; Jolin, Hina A; Huebner, Dirk; Radford, John; Luminari, Stefano. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 378:4(2018), pp. 331-344. [10.1056/NEJMoa1708984]

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

luminari, Stefano
Membro del Collaboration Group
2018

Abstract

Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma.
2018
10-dic-2017
378
4
331
344
WOS:000423233400006
2-s2.0-85041389324
29224502
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma / Connors, Joseph M; Jurczak, Wojciech; Straus, David J; Ansell, Stephen M; Kim, Won S; Gallamini, Andrea; Younes, Anas; Alekseev, Sergey; Illés, Árpád; Picardi, Marco; Lech-Maranda, Ewa; Oki, Yasuhiro; Feldman, Tatyana; Smolewski, Piotr; Savage, Kerry J; Bartlett, Nancy L; Walewski, Jan; Chen, Robert; Ramchandren, Radhakrishnan; Zinzani, Pier L; Cunningham, David; Rosta, Andras; Josephson, Neil C; Song, Eric; Sachs, Jessica; Liu, Rachael; Jolin, Hina A; Huebner, Dirk; Radford, John; Luminari, Stefano. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 378:4(2018), pp. 331-344. [10.1056/NEJMoa1708984]
Connors, Joseph M; Jurczak, Wojciech; Straus, David J; Ansell, Stephen M; Kim, Won S; Gallamini, Andrea; Younes, Anas; Alekseev, Sergey; Illés, Árpád;...espandi
File in questo prodotto:
File Dimensione Formato  
10.1056@NEJMoa1708984.pdf

Open Access dal 02/06/2018

Descrizione: Articolo principale
Tipologia: VOR - Versione pubblicata dall'editore
Dimensione 331.74 kB
Formato Adobe PDF
Visualizza/Apri
331.74 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1152776
Citazioni
  • ???jsp.display-item.citation.pmc??? 153
  • Scopus 590
  • ???jsp.display-item.citation.isi??? 558
social impact